Literature DB >> 30406639

Rutosides for prevention of post-thrombotic syndrome.

Joanne R Morling1, Su Ern Yeoh, Dinanda N Kolbach.   

Abstract

BACKGROUND: Post-thrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT) that is characterised by pain, swelling, and skin changes in the affected limb. One in three patients with DVT will develop post-thrombotic sequelae within five years. The current standard care for the prevention of PTS following DVT is elastic compression stockings. Rutosides are a group of compounds derived from horse chestnut (Aesculus hippocastanum), a traditional herbal remedy for treating oedema formation in chronic venous insufficiency (CVI). However, it is not known whether rutosides are effective and safe in the prevention of PTS. This is the second update of the review first published in 2013.
OBJECTIVES: To determine the effectiveness and safety of rutosides for prevention of post-thrombotic syndrome (PTS) in patients with deep vein thrombosis (DVT), compared to placebo, no intervention, or reference medication. SEARCH
METHODS: The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 21 August 2018. SELECTION CRITERIA: We planned to include trials of rutosides versus any alternative (placebo, no intervention, or reference medication) in the prevention of PTS in patients with DVT. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for inclusion and intended to extract information from the trials. MAIN
RESULTS: No studies were identified comparing rutosides versus any alternative in the prevention of PTS. AUTHORS'
CONCLUSIONS: As there were no studies identified in this review there is currently insufficient evidence to determine the effectiveness and safety of rutosides for prevention of PTS in patients with DVT. Some studies suggest that rutosides may provide short-term relief of PTS symptoms. However, there is nothing published on their use as a preventative therapy for PTS. High quality randomised controlled trials of rutoside versus any alternative are required to build the evidence base in this area.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30406639      PMCID: PMC6516967          DOI: 10.1002/14651858.CD005626.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  20 in total

Review 1.  Compression therapy for prevention of post-thrombotic syndrome.

Authors:  Diebrecht Appelen; Eva van Loo; Martin H Prins; Martino Ham Neumann; Dinanda N Kolbach
Journal:  Cochrane Database Syst Rev       Date:  2017-09-26

2.  Haemoconcentration and accumulation of white cells in the feet during venous stasis.

Authors:  C Moyses; S A Cederholm-Williams; C C Michel
Journal:  Int J Microcirc Clin Exp       Date:  1987

3.  White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin.

Authors:  P R Thomas; G B Nash; J A Dormandy
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-18

4.  [The active therapeutic principle of horse chestnut (Aesculus hippocastanum). Part 1. Classification of the active substance].

Authors:  D LORENZ; M L MAREK
Journal:  Arzneimittelforschung       Date:  1960-04

5.  Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency.

Authors:  R M Facino; M Carini; R Stefani; G Aldini; L Saibene
Journal:  Arch Pharm (Weinheim)       Date:  1995-10       Impact factor: 3.751

Review 6.  Rutosides for prevention of post-thrombotic syndrome.

Authors:  Joanne R Morling; Su Ern Yeoh; Dinanda N Kolbach
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

7.  [Comparison of the bioavailability of beta-aescin after single oral administration of two different drug formulations containing an extract of horse-chestnut seeds].

Authors:  E Schrader; W Schwankl; C Sieder; V Christoffel
Journal:  Pharmazie       Date:  1995-09       Impact factor: 1.267

Review 8.  Rutosides for prevention of post-thrombotic syndrome.

Authors:  Joanne R Morling; Su Ern Yeoh; Dinanda N Kolbach
Journal:  Cochrane Database Syst Rev       Date:  2015-09-16

9.  Rutosides for treatment of post-thrombotic syndrome.

Authors:  Joanne R Morling; Cathryn Broderick; Su Ern Yeoh; Dinanda N Kolbach
Journal:  Cochrane Database Syst Rev       Date:  2018-11-08

Review 10.  Horse chestnut seed extract for chronic venous insufficiency.

Authors:  Max H Pittler; Edzard Ernst
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more
  2 in total

1.  Rutosides for prevention of post-thrombotic syndrome.

Authors:  Joanne R Morling; Su Ern Yeoh; Dinanda N Kolbach
Journal:  Cochrane Database Syst Rev       Date:  2018-11-08

2.  Rutosides for treatment of post-thrombotic syndrome.

Authors:  Joanne R Morling; Cathryn Broderick; Su Ern Yeoh; Dinanda N Kolbach
Journal:  Cochrane Database Syst Rev       Date:  2018-11-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.